Oral Mucosa Graft Selection Using VEGF and Cytokeratin Markers

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for producing transplantable oral mucosa tissue lack the ability to ensure sufficient quality and consistency, leading to variable treatment outcomes, particularly in applications like urethral reconstruction and cornea implantation.

Innovation Solution

A method for selecting oral mucosa tissue using markers such as vascular endothelial growth factor (VEGF) concentration and cytokeratin expression levels to determine cell potency and purity, ensuring the production of high-quality transplantable oral mucosa tissue.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing methods for producing transplantable oral mucosa tissue are used, then tissue production is achieved, but quality and consistency are insufficient leading to variable treatment outcomes

Engineering Contradiction:

Improvetreatment outcome consistencyVSAvoidtissue quality control

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent applies parameter changes by establishing specific quantitative thresholds for VEGF concentration (≥10 pg/ml) and cytokeratin expression levels to define suitable oral mucosa tissue. These parameter specifications transform the tissue selection process from qualitative assessment to quantitative control, ensuring consistent treatment outcomes through standardized manufacturing parameters.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces traditional mechanical or manual tissue assessment methods with biochemical marker detection systems. By using immunoassays or molecular biology techniques to detect VEGF and cytokeratin levels, the invention substitutes subjective evaluation with objective, measurable biochemical parameters, thereby improving manufacturing precision and reliability.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If oral mucosa tissue is cultured to generate transplantable tissue, then tissue quantity is increased, but non-epithelial cell contamination may occur

Engineering Contradiction:

Improvetissue production volumeVSAvoidcell purity

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The patent implements feedback control by using cytokeratin expression levels as a quality indicator during the tissue culture process. By monitoring cytokeratin levels throughout cultivation, the method provides continuous feedback on epithelial cell purity, allowing for real-time adjustments to maintain high-quality transplantable tissue while maximizing production volume.

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent uses cytokeratin and VEGF as intermediary markers to indirectly assess tissue quality and purity. These biochemical markers serve as mediators between the complex cellular composition and the final quality assessment, enabling precise control of cell purity without requiring direct microscopic examination of every cell in the cultured tissue.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12582750B2Method for producing transplantable oral mucosa tissue

Publication Date: 2026.03.24 MUKOCELL GMBH

AI summary

The present invention relates to a method for producing transplantable oral mucosa tissue by selecting and choosing from oral mucosa biopsy, and to the use thereof as pharmaceutical composition, medicament or transplant or graft material, in particular for urethral reconstruction or cornea implantation. In particular, the invention relates to markers for identifying suitable transplantable oral mucosa tissue for the production of transplantable oral mucosa tissue, in particular for producing an autologous oral mucosa graft or tissue.